OncologyOnline.net

Oncology Xagena

Patients with metastatic urothelial carcinoma have few treatment options after failure of Platinum-based chemotherapy. In this trial, researchers have assessed treatment with Atezolizumab, an engineer ...


Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs Lapatinib /( Tyverb; Tykerb ) and Trastuzumab ( Herceptin ) before surgery ...


The advent of new immunotherapies for the treatment of metastatic melanoma has resulted in various novel combination strategies. Because of their distinct modes of action, different immunotherapies ha ...


Treatment with programmed death receptor-1 ( PD-1 ) antibodies is associated with high response rates in patients with advanced melanoma. Reliable markers for early response and outcome are still spar ...


Updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( MPDL3280A ) in people with locally advanced or metastatic urothelial carcinoma ...


Trials of salvage therapy for advanced urothelial carcinoma have required prior Platinum-based therapy. This practice requires scrutiny since non-Platinum-based first-line therapy may be offered to Ci ...


The outcomes and therapy of advanced urothelial carcinoma ( UC ) patients following discontinuation of PD-1/PD-L1 inhibitors are unclear. Researchers performed a retrospective analysis to examine ...


The majority of patients with castration-resistant prostate cancer develop bone metastatic disease. It is often challenging to optimally palliate malignant bone pain. In case of multifocal pain due to ...


A study has assessed palliative selective and superselective arterial embolization with N-butyl-cyanoacrylate ( n-BCA ) for cancer patients with spinal metastases. Researchers studied the files of ...


Bone metastases are common in patients with non-small cell lung cancer ( NSCLC ), often causing pain and a decrease in quality of life ( QoL ). The effect of bone-targeted agents is evaluated by reduc ...


Results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in p ...


The purpose of GORTEC 2000-01 was to compare the long-term efficacy and safety of induction chemotherapy with Cisplatin ( P ) and 5-Fluorouracil ( F ) with or without Docetaxel ( T ) for larynx preser ...


Researchers conducted a phase IIb randomized trial of preoperative chemotherapy ( CT ) plus Trastuzumab ( T ), Lapatinib ( L ), or the combination of Trastuzumab plus Lapatinib in HER2+ operable breas ...


In the large pivotal phase II study, BIRCH, the investigational cancer immunotherapy Atezolizumab ( MPDL3280A; anti-PD-L1 ) met its primary endpoint and shrank tumors ( objective response rate; ORR ) ...


Longer term ( 18 month ) survival data from CheckMate -057, an open-label, randomized phase 3 study evaluating Nivolumab [ Opdivo ] ( n=292 ) versus Docetaxel [ Taxotere ] ( n=290 ) in previously trea ...


Results from CheckMate -025, a phase 3 study comparing Nivolumab ( Opdivo ) to Everolimus ( Afinitor ) in advanced renal cell carcinoma ( RCC ) after prior anti-angiogenic treatment, showed a signific ...


Positive results from two phase II studies that evaluated the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with advanced non-small cell lung cancer ( NSCLC ) we ...


Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with locally advanced or metastatic urothelial car ...


New data from KEYNOTE-001, a phase 1b study evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in naïve and previously-treated patients with advanced non-small cell lung cancer ( NSCLC ) wer ...


A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-base ...


Although activating mutations in the epidermal growth factor receptor ( EGFR ) gene are predictive markers for response to EGFR inhibitors, 30-40% of EGFR-mutant non-small cell lung cancer ( NSCLC ) p ...


T-DM1 ( Trastuzumab emtansine; Kadcyla ) treatment resulted in non-inferior, but not-superior, progression-free survival ( PFS ) compared with Trastuzumab plus a taxane ( HT ) in patients with locally ...


Results from two pivotal studies ( NP28673 and NP28761 ) have showen Alectinib, an oral investigational anaplastic lymphoma kinase inhibitor ( ALKi ), shrank tumours ( overall response rate; ORR: 50% ...


The immune-modulating effects of radiotherapy ( XRT ) have gained considerable interest, and there have been multiple reports of synergy between radiotherapy and immunotherapy. However, additional p ...


Management of the neck in early oral cancers has been a matter of debate with clinical equipoise between elective ( END ) or therapeutic neck dissection ( TND ). This is a prospective phase III RC ...


Cancer Drugs Fund ( CDF ) Panel has assessed the application was for single agent Pemetrexed ( Alimta ) to remain in the CDF as maintenance treatment for patients with locally advanced or metastatic ...


A new study has provided the first evidence that the mediator complex subunit 15 ( MED15 ) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma ( HNSCC ). MED15 ov ...


Axillary lymph node evaluation is performed frequently in women with ductal carcinoma in situ breast cancer, despite recommendations generally against such an assessment procedure in women with locali ...


In a study, researchers from Brigham and Women's Hospital ( BWH ) ( Boston, Massachusetts; USA ) have reported that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcino ...


Pembrolizumab ( Keytruda ), an anti–PD-1 antibody, demonstrated antitumor activity and acceptable safety in patients with recurrent or metastatic PD-L1–positive urothelial cancer enrolled in the phase ...


A review, titled Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential, from researchers at The University of Texas MD Anderson Cancer Center published i ...


Findings investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer ( SCLC ), esophageal cancer and o ...


Cancer Drugs Fund ( CDF ) Panel has assessed the application for single agent Pemetrexed ( Alimta ) to remain in the CDF as 2nd line treatment for patients with non-squamous ( NS ) non-small cell lun ...


Immune checkpoint blockade may play a role in the treatment of metastatic urothelial cancer ( mUC ). However, the role of CTLA4 blockade, the impact of chemotherapy on immune cell populations, and the ...


Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to remain in the CDF list as 3rd line chemotherapy for patients with locally advanced or metastatic breast c ...


The application was for Regorafenib ( Stivarga ) to remain in the Cancer Drugs Fund ( CDF ) as treatment for patients with non-resectable or metastatic gastrointestinal stromal tumours ( GISTs ) who w ...


The LUME-Lung 1 trial has demonstrated a significant overall survival advantage for Nintedanib ( Vargatef ) plus Docetaxel ( Taxotere ) compared with placebo plus Docetaxel as second-line therapy for ...


A study has compared the incidence of vascular thromboembolic events ( VTEs ) in patients with metastatic or unresectable urothelial carcinoma ( UC ) who were treated with Gemcitabine and Carboplatin ...


Afatinib ( Giotrif ) was compared with standard Platinum-based doublet chemotherapy in two large, randomized phase III studies, ie, LUX-Lung 3 and LUX-Lung 6, in patients with EGFR-mutant advanced non ...


The Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to enter the CDF as an option for patients with locally advanced or metastatic HER-2 negative breast can ...


Basal cell carcinomas are the most common skin cancers. They are usually localised and carry a good prognosis. There is no standard treatment for the rare patients with metastatic basal cell carcinoma ...


The efficacy and safety of Dabigatran ( Pradaxa ) for treatment of venous thromboembolism ( VTE ) were demonstrated in two trials. It is unclear if the results pertain to patients with cancer and veno ...


The FDA ( Food and Drug Administration ) has granted Priority Review for the New Drug Application ( NDA ) for Cobimetinib in combination with Vemurafenib ( Zelboraf ) for the treatment of people with ...


The FDA ( Food and Drug Administration ) has expanded the approved use of Opdivo ( Nivolumab ) to treat patients with advanced ( metastatic ) squamous non-small cell lung cancer ( NSCLC ) with progres ...


LUX-Lung 1 was a phase IIb/III study that looked at the benefit of Afatinib ( Giotrif ) and best supportive care in comparison with placebo and best supportive care, as a third-line or fourth-line the ...


Patients with melanoma brain metastases have a poor prognosis and historically have been excluded from clinical trials. The Expanded Access Program ( EAP ) provided an opportunity to evaluate the f ...


Although anti–CTLA-4 and anti–PD-1 monoclonal antibodies ( mAbs ) may overcome T-cell suppression, T-cell activation depends on the engagement of the antigen receptor and the activating costimulation ...


The efficacy of the ALK inhibitor, Crizotinib ( Xalkori ) as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer ( NSCLC ) is unknown. A ...


Nivolumab ( Opdivo ) is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. A phase II trial has assessed the antitumor acti ...


Elderly patients with metastatic melanoma have different disease characteristics and a poorer prognosis than younger patients. Data from clinical trials and expanded access programmes ( EAPs ) sugge ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati